Effectiveness of Esoguard in the complex treatment of gastroesophageal reflux disease with reflux esophagitis
https://doi.org/10.33667/2078-5631-2026-5-74-78
Abstract
Esophageal diseases are common among the population, particularly gastroesophageal reflux disease (GERD). Long-term GERD, delayed diagnosis, and inadequate treatment increase the risk of Barrett's esophagus and esophageal adenocarcinoma. Non-reflux-related esophageal diseases, such as infectious and eosinophilic esophagitis, are becoming increasingly common. Damage to the esophageal mucosa is caused by an imbalance between protective and aggressive factors. The main groups of drugs used to treat GERD include proton pump inhibitors (PPIs), potassium-competitive proton pump inhibitors, alginates, antacids, and prokinetic agents. Recently, a group of esophageal protectors based on hyaluronic acid and alginates has been actively used. We conducted a study to evaluate the effectiveness of combination therapy for reflux esophagitis B-D associated with GERD, including a proton pump inhibitor (PPI) and the domestically produced esophageal protector Ezogard. Adding the esophageal protector Ezogard to the combination GERD treatment (lifestyle and PPI) for one month results in faster relief of the main symptom – heartburn – and more effective healing of esophageal mucosal erosions.
About the Authors
M. F. Osipenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
Osipenko Marina F., Dr Med Sci (habil.), professor, head of Dept of Propaedeutics of Internal Diseases
Novosibirsk
E. A. Bikbulatova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Bikbulatova Elena A., PhD Med Sci, associate professor at Dept of Propaedeutics of Internal Diseases
Novosibirsk
V. V. Leontyev
City Clinical Polyclinic № 1
Russian Federation
Russian Federation
Leontyev Vladislav V., head of Gastroenterology Dept.
Novosibirsk
Ya. A. Krasner
Novosibirsk State Medical University
Russian Federation
Russian Federation
Krasner Yakov A., PhD Med Sci, associate professor at Dept of Propaedeutics of Internal Diseases
Novosibirsk
L. Yu. Pankova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Pankova Lada Yu., PhD Med Sci, associate professor at Dept of Propaedeutics of Internal Diseases
Novosibirsk
References
1. Douglas A. Drossman Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV Gastroenterology 2016; 150: 1262–1279.
2. Ivashkin V. T., Trukhmanov A. S., Maev I. V., Drapkina O. M., Livzan M. A., Martynov A. I., Lapina T. L., Paraskevova A. V., Andreev D. N., Alekseeva O. P., Alekseenko S. A., Baranovsky A. Yu., Zairatyants O. V., Zolnikova O. Yu., Dronova O. B., Klyaritskaya I. L., Korochanskaya N. V., Kucheryavyi Yu.A., Mammaev S. N., Osipenko M. F., Pirogov S. S., Poluektova E. A., Rumyantseva D. E., Sayfutdinov R. G., Storonova O. A., Uspensky Yu.P., Khlynov I. B., Tsukanov V. V., Sheptulin A. A. Diagnosis and treatment of gastroesophageal reflux disease (Recommendations of the Russian Gastroenterological Association, Russian Scientific Medical Society of Therapists, Russian Society for the Prevention of Non-Communicable Diseases, Scientific Community for the Study of the Human Microbiome). Russian Journal of Gastroenterology, Hepatology, Proctology. 2024; 34 (5): 111–135. (In Russ.). https://doi.org/10.22416/1382-4376-2024-34-5-111-135
3. Tsukanov V. V., Vasyutin A. V., Tonkikh Yu. L. New international guidelines for the management of patients with gastroesophageal reflux disease: diagnosis and treatment of typical syndromes. Doctor.Ru. 2022; 21 (6): 29–34. (In Russ.).
4. Storonova O. A., Trukhmanov A. S., Dzhakhaya N. L. Esophageal clearance disorders in gastroesophageal reflux disease and the possibilities of their correction. RZhGGK. 2012; 2: 14–21. (In Russ.).
5. Lazebnik L. B., Masharova A. A., Bordin D. S. et al. Results of the Multicenter Study «Epidemiology of Gastroesophageal Reflux Disease in Russia» (MEGRE). Therapeutic Archives. 83 (1): 45–50. (In Russ.).
6. Isakov V. A., Morozov S. V., Stavraki E. S., Komarov R. S. Analysis of the prevalence of heartburn: national epidemiological study of the adult urban population (ARIADNA). Exp. Clin. Gastroenterol. 2008; 1:20–30. (In Russ.).
7. Bordin D. S., Abdulkhakov R. A., Osipenko M. F., Solovyova A. V., Abdulkhakov S. R., Kirilenko N.P., Butov M. A., Berezina O. I., Valitova E. R., Safina D. D., Alieva I. M., Livzan M. A., Sarsenbaeva A. S., Tarasova G. N., Embutnieks Yu.V., Mubarakshina I. R., Khairullin I. Kh., Kononova A. G., Kolbasnikov S. V., Maev I. V. Multicenter study of the prevalence of symptoms of gastroesophageal reflux disease in patients at clinics in Russia. Therapeutic archive. 2022; 94 (1): 48–56. (In Russ.). DOI: 10.26442/00403660.2022.01.201322
8. Joseph Mermelstein et al Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions/Clin Exp Gastroenterol. 2018; 11: 119–134Postgrad Med J. 2021 Jun; 97 (1148): 349–350.
9. Kyung Hwa Jung, et al. Can endoscopists differentiate cytomegalovirus esophagitis from herpes simplex virus esophagitis based on gross endoscopic findings? Medicine (Baltimore). 2019 Jun; 98 (23).
10. Cristina TargaFerreira Eosinophilic esophagitis – Where are we today? Esofagite eosinofílica – Qual é a nossa posição atual? Jornal de Pediatria Volume. 2019; 95 (3): 275–28.
11. Matoshina I. V., Livzan M. A., Fedorin M. M., Lapteva I. V. Clinically significant stigmas of GERD severity and dissociation with the degree of damage to the esophageal mucosa – is esophagoprotection mandatory? Experimental and Clinical Gastroenterology. 2021. No. 6 (190). P. 5–11. (In Russ.).
12. David Garrod, Martyn Chidgey Desmosome structure, composition and function Biochimica et Biophysica Acta 1778; 2008: 572–587.
13. Di Simone MP, Baldi F, Vasina V, et al. Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterol. 2012; 5: 103–107. DOI: 10.2147/CEG.S31404
14. Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017; 30 (5): 1–9. 9.
15. Batchelor HK, Banning D, Dettmar PW, Hampson FC, Jolliffe IG, Craig DQM. An in vitro mucosal model for prediction of the bioadhesion of alginate solutions to the oesophagus. Int J Pharm. 2002; 238 (1): 123–132. 11. (14).
16. Gabriella Guelfi et al. Gold nanoparticles approach to detect chondroitin sulphate and hyaluronic acid urothelial coating Sci Rep. 2017 Sep 4; 7 (1): 10355.
17. Noelia M Sanchez-Ballester, Bernard Bataille, Ian Soulairol.Sodium alginate and alginic acid as pharmaceutical excipients for tablet formulation: Structure-function relationship Carbohydr Polym. 2021 Oct 15; 270: 118399.
18. Muhammad Umar Aslam Khan et al. Sodium alginate-f-GO composite hydrogels for tissue regeneration and antitumor applications Int J Biol Macromol. 2022 May 31; 208: 475–485.
19. Peter Ian Chater et al. Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin Carbohydr Polym. 2015 Oct 20; 131: 142–151.
20. Manfred Gross et al. Multicentre prospective study to evaluate effectiveness and safety of gel-forming and hyaluronic-acid containing chewable tablets as add-on treatment in patients with gastroesophageal reflux disease (GERD) symptoms and unsatisfying proton pump inhibitor therapy/ BMC Gastroenterol. 2023 Sep 6; 23 (1): 304.
21. Tiziana Maria Grazia Pecora et al. Rheological Behavior of a New Mucoadhesive Oral Formulation Based on Sodium Chondroitin Sulfate, Xyloglucan and Glycerol J Funct Biomater. 2021 Apr 28; 12 (2): 28.
22. S Bordin, D N Andreev, I V Maev. Efficacy of esophagus protection in complex treatment of erosive gastroesophageal reflux disease: a systematic review and meta-analysis of controlled trials. Ter Arkh. 2023 Jan 16; 94 (12): 1407–1412.
Review
For citations:
Osipenko M.F., Bikbulatova E.A., Leontyev V.V., Krasner Ya.A., Pankova L.Yu. Effectiveness of Esoguard in the complex treatment of gastroesophageal reflux disease with reflux esophagitis. Medical alphabet. 2026;(5):74-78. (In Russ.) https://doi.org/10.33667/2078-5631-2026-5-74-78
Views:
79
JATS XML
Email this article 